Immunotherapy and Cervical Cancer.

Cervical cancer is the third most common cancer in women worldwide. Cervical cancer is a disease that develops quite slowly and begins with a precancerous condition known as dysplasia. Dysplasia is easily detected in a routine Pap smear and is completely treatable. Cervical cancer is a malignant tumor deriving from cells of the cervix( lower part of the uterus).

 

www.gapsos.com

The primary etiological agent is HPV and its precursor lesions for cervical cancer, which leads the development of the control of cervical cancer cells. With the help of HPV vaccine clinical trials data, we easily to identify the characteristics and mechanisms of the immune response. The complete perspective of immunotherapy treatment has not been utilized. Clinical studies are the import factor in understanding the future of immunotherapy (immune- Oncology) in treating cancer patients. 

To stimulate immunity against cervical cancer in treatment by using immunotherapy based drugs and vaccines involve Bevacizumab (vascular endothelial growth factor-specific angiogenesis inhibitor) which has received FDA approval for the treatment of cervical cancer, in combination with paclitaxel and topotecan or paclitaxel and cisplatin in recurrent disease. Some warnings are included like surgery and wound healing complications, Gastrointestinal perforations, and hemorrhage with some common adverse reactions are hypertension, back pain, headache, taste alteration, dry skin and rectal hemorrhage. Gardasil is a vaccine has received FDA approval for the treatment of cervical cancers caused by Human Papillomavirus (HPV) types 16 and 18. With contraindications like hypersensitivity. Also, having Warning involves Syncope sometimes associated with tonic-clonic movements with most common adverse reaction involves headache, swelling, erythema, fever and nausea.

Some drugs and vaccines are under clinical trials in cervical cancer. Ipilimumab (NCT01693783) is running in phase II under safety and efficacy study design, which targets to kill cancer cells. Ipilimumab with Cisplatin (NCT01711515) is running in phase I under safety study design, which targets to the  growth of cancer cells. VGX-3100 and INO-9012 DNA vaccine (NCT02172911) is running in phase I and II under safety and efficacy study, which targets to HPV-16 or 18-positive. Peptide vaccine (NCT00108875) is running in phase I and II under non randomized, safety and efficacy study, which targets to cancer cells.

Global Allied Pharmaceuticals(GAP) has the advance technology and the expert team of immunotherapy and immune-oncology. Our team has capability for new development of the immunotherapeutic cancer agents. Our expert team easily understand the molecular basis of the interactions between targeted anti-cancer agents and the immune system and also helps the patients in planning their treatment strategy throughout their different types of solid tumor cancers like breast and prostate, melanoma, cervical and colorectal.

For more information kindly visit us at www.gapsos.com